Peristent Remodeling and Neointimal Suppression 2 Years After Polymer-Based, Paclitaxel-Eluting Stent Implantation: Insights From Serial Intravascular Ultrasound Analysis in the TAXUS II Study

Background— The purpose of this study was to evaluate long-term vascular responses as long as 2 years after implantation of polymer-based, paclitaxel-eluting stents in contrast to uncoated stents. Methods and Results— TAXUS II is a randomized, double-blind trial comparing slow-release (SR) and moderate-release (MR) TAXUS stents with bare-metal control stents (BMSs). One hundred sixty-one event-free patients (SR, 43; MR, 41; and BMS, 77) underwent serial intravascular ultrasound (IVUS) analysis after the procedure and at 6 months and 2 years. At 2 years, neointimal responses continued to be significantly suppressed in the SR and MR groups when compared with the BMS group (BMS, 1.49±1.12 mm2; SR, 0.94±0.76 mm2 [P=0.004]; and MR, 1.06±0.90 mm2 [P=0.02]). Between 6 months and 2 years, the BMS group showed compaction of the neointima (&Dgr;, −0.22±1.05 mm2 [P=0.08]). In contrast, both the SR and MR groups exhibited an increase (&Dgr; SR, 0.30±0.76 mm2 (P=0.01); MR, 0.41±0.94 mm2 [P=0.009]). Between 6 months and 2 years, the initial increase in plaque outside the stent regressed in the BMS and SR groups to levels comparable to those after the procedure, whereas expansive remodeling partially regressed in the MR group (&Dgr; between after the procedure and 2 years BMS, −0.34±1.28 mm2 [P=0.05]; SR, −0.02±1.40 mm2 [P=0.93]; MR, 0.32±1.56 mm2 [P=0.27]). Conclusions— The 2-year follow-up demonstrates that neointimal suppression was dose independent and that this effect was still sustained at 2 years. However, the increase in area outside the stent seen at 6 months regressed to different extents in a dose-dependent manner at 2 years.

[1]  Patrick W Serruys,et al.  Four-Year Angiographic and Intravascular Ultrasound Follow-Up of Patients Treated With Sirolimus-Eluting Stents , 2005, Circulation.

[2]  P. Serruys,et al.  Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents: Three-Year Results of the RAVEL Trial , 2005, Circulation.

[3]  P. Serruys,et al.  Incomplete Stent Apposition After Implantation of Paclitaxel-Eluting Stents or Bare Metal Stents: Insights From the Randomized TAXUS II Trial , 2005, Circulation.

[4]  P. Tsao,et al.  Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. , 2004, Cardiovascular research.

[5]  R. Virmani,et al.  Extracellular Matrix Changes in Stented Human Coronary Arteries , 2004, Circulation.

[6]  R. Whitbourn,et al.  Vascular Responses at Proximal and Distal Edges of Paclitaxel-Eluting Stents: Serial Intravascular Ultrasound Analysis From the TAXUS II Trial , 2004, Circulation.

[7]  K. Kent,et al.  Five-Year Follow-Up After Intracoronary Gamma Radiation Therapy for In-Stent Restenosis , 2004, Circulation.

[8]  P. Serruys,et al.  Chronic Arterial Responses to Polymer-Controlled Paclitaxel-Eluting Stents: Comparison With Bare Metal Stents by Serial Intravascular Ultrasound Analyses: Data From the Randomized TAXUS-II Trial , 2004, Circulation.

[9]  P. Serruys,et al.  Long-Term Follow-Up of Incomplete Stent Apposition in Patients Who Received Sirolimus-Eluting Stent for De Novo Coronary Lesions: An Intravascular Ultrasound Analysis , 2003, Circulation.

[10]  S. Silber,et al.  Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.

[11]  N. Weissman,et al.  Regional Remodeling as the Cause of Late Stent Malapposition , 2003, Circulation.

[12]  Antonio Colombo,et al.  Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in Humans , 2002, Circulation.

[13]  E. Tuzcu,et al.  Coronary Plaque Classification With Intravascular Ultrasound Radiofrequency Data Analysis , 2002, Circulation.

[14]  P. Serruys,et al.  Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) Trial , 2002, Circulation.

[15]  J. Tardif,et al.  Two-Year Angiographic Follow-Up of Intracoronary Sr90 Therapy for Restenosis Prevention After Balloon Angioplasty , 2002, Circulation.

[16]  P. Teirstein,et al.  Five-Year Clinical Follow-Up After Intracoronary Radiation: Results of a Randomized Clinical Trial , 2002, Circulation.

[17]  Nico Bruining,et al.  A novel approach to quantitative analysis of intra vascular ultrasound images , 2001, Computers in Cardiology 2001. Vol.28 (Cat. No.01CH37287).

[18]  M Schartl,et al.  Use of Intravascular Ultrasound to Compare Effects of Different Strategies of Lipid-Lowering Therapy on Plaque Volume and Composition in Patients With Coronary Artery Disease , 2001, Circulation.

[19]  R. Virmani,et al.  Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.

[20]  P. Fitzgerald,et al.  Impact of Peri-Stent Remodeling on Restenosis: A Volumetric Intravascular Ultrasound Study , 2001, Circulation.

[21]  R A Schatz,et al.  Three-year clinical and angiographic follow-up after intracoronary radiation : results of a randomized clinical trial. , 2000, Circulation.

[22]  M. Leon,et al.  Chronic arterial responses to stent implantation: a serial intravascular ultrasound analysis of Palmaz-Schatz stents in native coronary arteries. , 1996, Journal of the American College of Cardiology.

[23]  H Yokoi,et al.  Three-year follow-up after implantation of metallic coronary-artery stents. , 1996, The New England journal of medicine.